GSK’s Witty: China Moving Rapidly To ‘No Growth’ Status
This article was originally published in PharmAsia News
Executive Summary
Despite a first-quarter slump, GSK insists its China business is moving back to underlying growth, although the firm’s CEO warns the country's overall pharma market has "slowed down dramatically" and is moving quickly to "no-growth" status.
You may also be interested in...
GSK Foresees Return To Emerging Markets Growth
The second quarter saw continued declines in GSK's China and wider emerging markets business, but CEO Andrew Witty expects a return to growth in these sectors over the remainder of the year.
China Approves First HPV Vaccine But Can GSK Secure Its Lead?
After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.